Table II.
SNP, location (references) | Genotype | No. control (%) | No. cases (%) | OR (95% CI) | P | Ptrend | Dominant P | Recessive P |
8q24 SNPs previously associated with other cancers | ||||||||
rs620861, 128,404,855 (15,16) | G/G | 577 (40.4) | 49 (49.5) | 1 (ref) | ||||
A/G | 652 (45.6) | 39 (39.4) | 0.70 (0.45–1.08) | 0.11 | ||||
A/A | 201 (14.1) | 11 (11.1) | 0.64 (0.33–1.25) | 0.19 | 0.086 | 0.071 | 0.39 | |
rs13281615, 128,424,800 (19) | A/A | 445 (33.2) | 37 (39) | 1 (ref) | ||||
A/G | 656 (49) | 43 (45.3) | 0.79 (0.50–1.25) | 0.31 | ||||
G/G | 238 (17.8) | 15 (15.8) | 0.77 (0.41–1.42) | 0.39 | 0.31 | 0.27 | 0.64 | |
rs10505477, 128,476,625 (39,40) | G/G | 407 (28.5) | 24 (24.2) | 1 (ref) | ||||
A/G | 696 (48.7) | 52 (52.5) | 1.27 (0.77–2.09) | 0.35 | ||||
A/A | 326 (22.8) | 23 (23.2) | 1.19 (0.66–2.14) | 0.57 | 0.55 | 0.37 | 0.95 | |
rs7014346, 128,493,974 (41,42) | G/G | 632 (44.3) | 37 (37.4) | 1 (ref) | ||||
A/G | 614 (43) | 48 (48.5) | 1.35 (0.87–2.10) | 0.19 | ||||
A/A | 182 (12.8) | 14 (14.1) | 1.30 (0.69–2.46) | 0.42 | 0.25 | 0.17 | 0.73 | |
rs1447295, 128,554,220 (20,43,44) | C/C | 1165 (81.5) | 77 (77.8) | 1 (ref) | ||||
A/C | 253 (17.7) | 22 (22.2) | 1.35 (0.82–2.21) | 0.24 | ||||
A/A | 11 (0.8) | 0 (0) | 0 | 0.44 | 0.32 | 0.22 | ||
rs6983267, 128,482,487 (20,40,45) | T/T | 389 (27.2) | 23 (23.2) | 1 (ref) | ||||
G/T | 702 (49.1) | 51 (51.5) | 1.23 (0.74–2.04) | 0.43 | ||||
G/G | 339 (23.7) | 25 (25.2) | 1.24 (0.69–2.22) | 0.47 | 0.47 | 0.39 | 0.75 | |
rs4242382, 128,586,755 (46) | G/G | 1168 (81.7) | 77 (77.8) | 1 (ref) | ||||
A/G | 249 (17.4) | 22 (22.2) | 1.37 (0.83–2.24) | 0.22 | ||||
A/A | 12 (0.8) | 0 (0) | 0 | 0.43 | 0.31 | 0.2 | ||
rs7017300, 128,594,450 (23) | A/A | 1077 (75.4) | 67 (67.7) | 1 (ref) | ||||
A/C | 325 (22.7) | 31 (31.3) | 1.56 (0.99–2.42) | 0.051 | ||||
C/C | 27 (1.9) | 1 (1) | 0.59 (0.08–4.38) | 0.60 | 0.17 | 0.087 | 0.48 | |
rs7837688, 128,608,542 (23,47) | G/G | 1169 (81.8) | 78 (78.8) | 1 (ref) | ||||
G/T | 248 (17.4) | 21 (21.2) | 1.29 (0.78–2.13) | 0.32 | ||||
T/T | 12 (0.8) | 0 (0) | 0 | 0.57 | 0.43 | 0.21 | ||
8q24 SNPs associated with osteosarcoma | ||||||||
rs185852, 128,362,638 | G/G | 934 (65.4) | 60 (60.6) | 1 (ref) | ||||
A/G | 440 (30.8) | 31 (31.3) | 1.09 (0.70–1.71) | 0.69 | ||||
A/A | 54 (3.8) | 8 (8.1) | 2.28 (1.04–5.02) | 0.039 | 0.13 | 0.35 | 0.043 | |
rs896324, 128,465,694 | A/A | 1225 (85.7) | 76 (76.8) | 1 (ref) | ||||
A/G | 191 (13.4) | 21 (21.2) | 1.79 (1.08–2.97) | 0.025 | ||||
G/G | 13 (0.9) | 2 (2) | 2.75 (0.61-12.52) | 0.19 | 0.011 | 0.02 | 0.29 | |
rs10808555, 128,478,693 | A/A | 679 (47.5) | 37 (37.4) | 1 (ref) | ||||
A/G | 595 (41.6) | 52 (52.5) | 1.61 (1.04–2.48) | 0.033 | ||||
G/G | 156 (10.9) | 10 (10.1) | 1.17 (0.57–2.40) | 0.67 | 0.19 | 0.05 | 0.78 | |
rs17766217, 128,573,679 | T/T | 531 (37.2) | 47 (47.5) | 1 (ref) | ||||
C/T | 692 (48.4) | 42 (42.4) | 0.69 (0.45–1.07) | 0.096 | ||||
C/C | 206 (14.4) | 10 (10.1) | 0.56 (0.28–1.13) | 0.1 | 0.046 | 0.05 | 0.23 | |
rs12155672, 128,576,206 | G/G | 366 (25.6) | 23 (23.2) | 1 (ref) | ||||
A/G | 728 (50.9) | 42 (42.4) | 0.92 (0.55–1.56) | 0.76 | ||||
A/A | 336 (23.5) | 34 (34.3) | 1.59 (0.92–2.76) | 0.098 | 0.079 | 0.6 | 0.022 | |
rs7386167, 128,637,894 | G/G | 618 (43.2) | 37 (37.4) | 1 (ref) | ||||
A/G | 626 (43.8) | 40 (40.4) | 1.07 (0.67–1.69) | 0.78 | ||||
A/A | 186 (13) | 22 (22.2) | 1.95 (1.12–3.39) | 0.018 | 0.041 | 0.26 | 0.018 | |
rs9642880, 128,787,250 | G/G | 416 (29.2) | 39 (39.4) | 1 (ref) | ||||
G/T | 704 (49.4) | 42 (42.4) | 0.63 (0.40–0.99) | 0.048 | ||||
T/T | 306 (21.5) | 18 (18.2) | 0.62 (0.35–1.11) | 0.11 | 0.065 | 0.034 | 0.43 |
Statistically significant (P < 0.05) SNPs are shown in bold. The ORs and 95% CIs for the SNPs with P < 0.05 in the dominant or recessive models are noted in the text. For SNPs previously associated with other cancers, the representative references for the primary cancer association are cited. No., number; ref, referent genotype.